TY  - JOUR
T1  - REaligning incentives for developing and pricing new anticancer treatments
AU  - Howard DH
Y1  - 2011/06/08
N1  - 10.1001/jama.2011.793
JO  - JAMA
SP  - 2347
EP  - 2348
VL  - 305
IS  - 22
N2  - 
The Centers for Medicare & Medicaid Services (CMS) proposed in late March that Medicare cover sipuleucel-T, a new therapy for patients with terminal prostate cancer. Three independently conducted randomized controlled trials found that sipuleucel-T extends survival by 3 to 5 months. But the price is $93 000 for a course of therapy.1 It is probably pure coincidence that the announcement occurred as Congress was locked in intense negotiations over the budget, but few recent developments better symbolize the challenges facing lawmakers who want to rein in Medicare spending.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.793
UR  - http://dx.doi.org/10.1001/jama.2011.793
ER  -